within Pharmacolibrary.Drugs.ATC.J;

model J01DH52
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 12.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2000 / 1000000,
    adminCount     = 1,
    Vd             = 0.0202,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Meropenem and vaborbactam is a combination antibacterial drug consisting of meropenem, a broad-spectrum carbapenem antibiotic, and vaborbactam, a β-lactamase inhibitor. This combination is used for the treatment of complicated urinary tract infections, including pyelonephritis, caused by susceptible Gram-negative bacteria. The combination is approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are described for healthy adult subjects (average age ~35 years, both sexes) after intravenous administration.</p><h4>References</h4><ol><li><p>Rubino, CM, et al., &amp; Griffith, DC (2018). Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment. <i>Antimicrobial agents and chemotherapy</i> 62(3) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.02103-17&quot;>10.1128/AAC.02103-17</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29311069/&quot;>https://pubmed.ncbi.nlm.nih.gov/29311069</a></p></li><li><p>Zhuang, L, et al., &amp; Wang, Y (2020). Evaluation of Hemodialysis Effect on Pharmacokinetics of Meropenem/Vaborbactam in End-Stage Renal Disease Patients Using Modeling and Simulation. <i>Journal of clinical pharmacology</i> 60(8) 1011–1021. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1595&quot;>10.1002/jcph.1595</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32149406/&quot;>https://pubmed.ncbi.nlm.nih.gov/32149406</a></p></li><li><p>Volpicelli, L, et al., &amp; Oliva, A (2024). Simultaneous post-neurosurgical ventriculitis and bacteraemia by two different strains of KPC-producing K. pneumoniae successfully treated with meropenem/vaborbactam and high dose of fosfomycin. <i>Journal of global antimicrobial resistance</i> 37 86–90. DOI:<a href=&quot;https://doi.org/10.1016/j.jgar.2024.03.003&quot;>10.1016/j.jgar.2024.03.003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38519025/&quot;>https://pubmed.ncbi.nlm.nih.gov/38519025</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01DH52;
